{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:38:10Z","timestamp":1790401090398,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jaci.2024.11.013","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T20:56:43Z","timestamp":1731704203000},"page":"12-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Updated review of omalizumab to treat uncontrolled pediatric allergic asthma"],"prefix":"10.1016","volume":"155","author":[{"given":"Bradley E.","family":"Chipps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan Farrell","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tmirah","family":"Haselkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.11.013_bib2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ppul.26295","article-title":"Pediatric pulmonology 2021 year in review: asthma","volume":"58","author":"Stephenson","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaci.2024.11.013_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.11.013_bib6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaip.2014.02.011","article-title":"Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma","volume":"2","author":"Luskin","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.013_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaip.2017.05.027","article-title":"Asthma exacerbations and triggers in children in TENOR: impact on quality of life","volume":"6","author":"Chipps","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.013_bib8","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201901-0016OC","article-title":"The projected economic and health burden of uncontrolled asthma in the United States","volume":"200","author":"Yaghoubi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/pai.13532","article-title":"The economic burden of allergic comorbidities in pediatric severe asthma","volume":"32","author":"Pamuk","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2500\/aap.2018.39.4147","article-title":"Allergic sensitization and clinical outcomes in urban children with asthma, 2013-2016","volume":"39","author":"Nagarajan","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2024.11.013_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11882-009-0081-7","article-title":"Pathogenesis of allergic airway inflammation","volume":"10","author":"Agrawal","year":"2010","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2024.11.013_bib12","series-title":"Allergic diseases\u2014from basic mechanisms to comprehensive management and prevention","first-page":"69","article-title":"A current perspective of allergic asthma: from mechanisms to management","author":"Papdopoulos","year":"2021"},{"key":"10.1016\/j.jaci.2024.11.013_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2015-2354","article-title":"Changing trends in asthma prevalence among children","volume":"137","author":"Akinbami","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2024.11.013_bib14","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/all.15807","article-title":"Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"78","author":"Ho Shin","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.11.013_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2017.02.019","article-title":"The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up","volume":"140","author":"Peters","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib16","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic rhinitis and its impact on asthma (ARIA) guidelines\u20142016 revision","volume":"140","author":"Brozek","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/17476348.2017.1381564","article-title":"The role of upper airway pathology as a co-morbidity in severe asthma","volume":"11","author":"Licari","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/all.13370","article-title":"Comorbid \u201ctreatable traits\u201d in difficult asthma: current evidence and clinical evaluation","volume":"73","author":"Tay","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.11.013_bib19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/17476348.2019.1604227","article-title":"What are the effects of rhinitis on patients with asthma?","volume":"13","author":"Licari","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib21","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03130-2021","article-title":"Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients","volume":"60","author":"Humbert","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.11.013_bib25","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/all.13678","article-title":"Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study","volume":"74","author":"Deschildre","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.11.013_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.5114\/ada.2021.107929","article-title":"Effectiveness of omalizumab in children and adolescents with uncontrolled allergic asthma: a case series from Poland","volume":"38","author":"Sztafi\u0144ska","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaci.2024.11.013_bib27","doi-asserted-by":"crossref","DOI":"10.2174\/18743064-v16-e2206130","article-title":"Real-life effectiveness of omalizumab in patients with severe allergic asthma: RELIEF study","volume":"16","author":"Ahmad","year":"2022","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.jaci.2024.11.013_bib28","first-page":"1141","article-title":"Clinical experience with anti-ige monoclonal antibody (omalizumab) in pediatric severe allergic asthma\u2014a Romanian perspective","volume":"8","author":"Berghea","year":"2021","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jaci.2024.11.013_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/02770903.2018.1553051","article-title":"Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population","volume":"57","author":"Tarraf","year":"2018","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2024.11.013_bib30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1080\/02770903.2020.1789875","article-title":"Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis","volume":"58","author":"Fu","year":"2020","journal-title":"J Asthma"},{"key":"10.1016\/j.jaci.2024.11.013_bib31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12890-022-02246-x","article-title":"Real-world effectiveness of omalizumab for severe allergic asthma treatment in Columbia","volume":"22","author":"Torres-Duque","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib32","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.jaip.2020.03.051","article-title":"Aeroallergen sensitization, serum IgE, and eosinophilia as predictors of response to omalizumab therapy during the fall season among children with persistent asthma","volume":"8","author":"Sheehan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.013_bib33","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib34","first-page":"2673","article-title":"Treatment benefit with omalizumab in children by indicators of asthma severity","volume":"8","author":"Szefler","year":"2020"},{"key":"10.1016\/j.jaci.2024.11.013_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.11.013_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00730-2018","article-title":"Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIRE says no","volume":"51","author":"Busse","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.11.013_bib37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.013_bib38","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jaip.2020.10.027","article-title":"Possible protective effect of omalizumab on lung function decline in patients experiencing asthma exacerbations","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.013_bib39","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/pai.13484","article-title":"Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma","volume":"32","author":"Nieto-Garc\u00eda","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.aller.2018.09.009","article-title":"\u201cReal-life\u201d experience in asthmatic children treated with omalizumab up to six-years follow-up","volume":"47","author":"Folqu\u00e9","year":"2019","journal-title":"Allergo Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2024.11.013_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.alit.2021.01.001","article-title":"Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: a post-marketing surveillance","volume":"70","author":"Nakamura","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2024.11.013_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/JAA.S406628","article-title":"Real-world safety and effectiveness of omalizumab in moderate to severe allergic asthma patients in China: a post-authorization study","volume":"16","author":"Su","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2024.11.013_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/ACI.0000000000000970","article-title":"What\u2019s new in pediatric asthma and rhinitis phenotypes and endotypes?","volume":"24","author":"Roberto","year":"2024","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.1033511","article-title":"Severe pediatric asthma therapy; omalizumab\u2014a systematic review and meta-analysis of efficacy and safety profile","volume":"10","author":"Fenu","year":"2023","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2024.11.013_bib45","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaci.2016.07.035","article-title":"Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect","volume":"139","author":"Sly","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib48","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1542\/peds.110.5.e55","article-title":"Omalizumab improves asthma-related quality of life in children with allergic asthma","volume":"110","author":"Lemanske","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2024.11.013_bib49","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1081-1206(10)62175-8","article-title":"Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma","volume":"91","author":"Berger","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1177\/0009922809339054","article-title":"Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate\u2014severe allergic asthma","volume":"48","author":"Massanari","year":"2009","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.jaci.2024.11.013_bib51","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/03007991003771338","article-title":"Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma","volume":"26","author":"Kulus","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2024.11.013_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2010.539502","article-title":"Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma","volume":"27","author":"Milgrom","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jaci.2024.11.013_bib53","first-page":"2577","article-title":"[Clinical study of omalizumab combined with budesonide formoterol powder inhaler in the treatment of children with moderate and severe allergic asthma]. In Chinese","volume":"37","author":"Zhang","year":"2021","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2024.11.013_bib54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.24976\/Discov.Med.202335176.24","article-title":"Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma: a systematic review and meta-analysis","volume":"35","author":"Lang","year":"2023","journal-title":"Discov Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib55","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2500\/aap.2017.38.4067","article-title":"Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review","volume":"38","author":"Corren","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2024.11.013_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/pai.2008.0502","article-title":"Omalizumab treatment in children 6 to 18 years old with severe asthma at a children\u2019s medical center","volume":"21","author":"Campbell","year":"2008","journal-title":"Pediatr Asthma Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2500\/aap.2012.33.3500","article-title":"Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents","volume":"33","author":"Steiss","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2024.11.013_bib58","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/archdischild-2011-301570","article-title":"The oral corticosteroid-sparing effect of omalizumab in children with severe asthma","volume":"97","author":"Brodlie","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2024.11.013_bib59","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1183\/09031936.00149812","article-title":"Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey","volume":"42","author":"Deschildre","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.11.013_bib60","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1183\/09031936.00008115","article-title":"Real-life long-term omalizumab therapy in children with severe allergic asthma","volume":"46","author":"Deschildre","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.11.013_bib61","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.alit.2015.05.006","article-title":"Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy","volume":"64","author":"Odajima","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2024.11.013_bib62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/08971900211038251","article-title":"Effectiveness and safety studies of omalizumab in children and adolescents with moderate-to-severe asthma","volume":"36","author":"Cheng","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jaci.2024.11.013_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.15586\/aei.v50i6.495","article-title":"Omalizumab and allergen immunotherapy for respiratory allergies: a mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)","volume":"50","author":"De Filippo","year":"2022","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.jaci.2024.11.013_bib64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.iac.2010.08.004","article-title":"The role of respiratory virus infections in childhood asthma inception","volume":"30","author":"Jackson","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5 suppl","key":"10.1016\/j.jaci.2024.11.013_bib65","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1067\/S0022-3476(03)00511-0","article-title":"Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease","volume":"143","author":"Simoes","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2024.11.013_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1465-9921-10-85","volume":"10","author":"Jartti","year":"2009","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2024.11.013_bib67","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1183\/09031936.00062714","article-title":"Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing","volume":"45","author":"Rossi","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2024.11.013_bib68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib69","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.jaip.2022.06.041","article-title":"Omalizumab is associated with improved asthma outcomes in children and adolescents with serum immunoglobulin E above dosing guidelines","volume":"10","author":"Atkinson","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.013_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106228","article-title":"Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation","volume":"100","author":"Phipatanakul","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jaci.2024.11.013_bib71","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jaci.2016.08.041","article-title":"Minimally important differences and risk levels for the composite asthma severity index","volume":"139","author":"Krouse","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib72","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib73","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1164\/rccm.202310-1730OC","article-title":"Biomarker predictors of clinical efficacy of the anti-IgE biologic omalizumab in severe asthma in adults: results of the SoMOSA study","volume":"210","author":"Djukanovi\u0107","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2024.11.013_bib74","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib75","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1159\/000525723","article-title":"Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level be used as a biological marker to decide discontinuing omalizumab treatment?","volume":"183","author":"Arslan","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2024.11.013_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2024.11.013_bib77","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American college of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society work group on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924012284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924012284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:50:29Z","timestamp":1750693829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924012284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0091674924012284"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.11.013","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated review of omalizumab to treat uncontrolled pediatric allergic asthma","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}